Skip to content

Study On The Effect of Mrudweeka Eye Drops For Dry Eyes

A Randomized Open Label Controlled Clinical Study To Evaluate The Efficacy Of Mrudweeka Arka Aschyotana In The Management Of Shushkakshipaka With Special Reference To Computer Vision Syndrome - Nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084186
Enrollment
30
Registered
2025-04-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H045- Stenosis and insufficiency of lacrimal passages

Interventions

None listed

Sponsors

Dr Kshama Jain
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects within the age group between 21 to 40 years irrespective of gender, caste, religion, and socio-economic status. Subjects having minimum of two symptoms as per diagnostic criteria. Subjects who are employed professionals with screen time of more than two hours per day during the use of VDT (computers) with history of twelve months. Subjects willing to participate in the study with informed consent.

Exclusion criteria

Exclusion criteria: Subjects with history of any intraocular surgery. Subjects having any ocular trauma. Subjects diagnosed with cases of any systemic and autoimmune disorders. Subjects diagnosed with inflammatory and infective ocular conditions. Subjects diagnosed with conditions like Cataracts, Corneal opacity, Keratoconus and Glaucoma. Subjects with Drug induced dry eyes. Subjects with Congenital lacrimal gland agenesis. Subjects who are pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Significant improvement in the signs and symptoms of Shushkakshipaka. Significant improvement in the signs and symptoms of Computer vision syndrome. Timepoint: Pre-assessment - 0th day 1st assessment 7th day 2nd assessment - 23rd day Post treatment - 30th day Follow up - 45th day

Secondary

MeasureTime frame
Generation of in-depth analyzed data on the different aspects of the disease. Generation of data on possible adverse drug reactions. Timepoint: Pre-assessment - 0th day 1st assessment 7th day 2nd assessment - 23rd day Post treatment - 30th day Follow up - 45th day

Countries

India

Contacts

Public ContactDr Geetha Kumari B

Sri Sri College Of Ayurvedic Science And Research, Bengaluru

ayurgeeta@gmail.com9480056218

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026